Multiple Myeloma

Most recent

Improved Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

A majority of patients with multiple myeloma (MM) relapse after therapy, and the duration of remission decreases with each line of therapy.1 Novel agents, including proteasome inhibitors (PIs) and immunomodulatory agents (IMIDs), have improved outcomes for patients...


Dr. Richard LeBlanc: Impressive Results from POLLUX Trial

The addition of daratumumab to lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) alone was evaluated in the POLLUX trial, a randomized, open-label, multicentre, phase III study. The population of the study included 569 patients with multiple...

Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for R/R MM among patients with 1–3 prior lines of therapy based on previous treatment exposure: Updated analysis of POLLUX

Moreau P, et al. ASH 2016:489 Background In a phase I/II study, 32 patients with relapsed or refractory (R/R) multiple myeloma (MM) were treated with daratumumab, lenalidomide, and dexamethasone (DRd), which induced rapid, deep, and durable responses with a manageable...

Twitter feed

Local #radiotherapy improves OS in metastatic #prostatecancer with low disease burden. #ESMO18
h J R
#Immunotherapy as first-line treatment in some metastatic #colorectal #cancers? #ESMO18
h J R
Genetic marker of #pancreaticcancer may predict #radiation therapy outcomes.
h J R
A shortcut to #cancer drug development: live tumour testing.
h J R
New #cancer #vaccine shows early promise for patients with #HER2-positive cancers.
h J R